Online inquiry

IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8445MR)

This product GTTS-WQ8445MR is a type of mRNA modified with 5-Methyl-CTP, which ecodes the monoclonal antibody that targets TLR3 Agonist. The antibody can be applied in Cervical dysplasia vaccine research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Mycobacterium tuberculosis variant bovis; Alphapapillomavirus 9
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ8445MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12213MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ7985MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ7943MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ4948MR IVTScrip™ mRNA-Anti-GP, c13C6-FR1-N(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA c13C6-FR1-N
GTTS-WQ5456MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ11018MR IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCLA-117
GTTS-WQ9278MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IMMU-132
GTTS-WQ4837MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BT-062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW